The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis
IntroductionCD7 chimeric antigen receptor T-cell (CAR-T cell) therapy is an emerging method for treating hematological malignancies, and is another breakthrough in CAR-T cell therapy.MethodsThis study summarizes the currently published clinical research results on CD7 CAR-T cells and evaluates the s...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1478888/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556781232291840 |
|---|---|
| author | Jile Liu Yuxin An Rui Sun Xiaomei Zhang Shujing Guo Xuejin Gao Mingfeng Zhao |
| author_facet | Jile Liu Yuxin An Rui Sun Xiaomei Zhang Shujing Guo Xuejin Gao Mingfeng Zhao |
| author_sort | Jile Liu |
| collection | DOAJ |
| description | IntroductionCD7 chimeric antigen receptor T-cell (CAR-T cell) therapy is an emerging method for treating hematological malignancies, and is another breakthrough in CAR-T cell therapy.MethodsThis study summarizes the currently published clinical research results on CD7 CAR-T cells and evaluates the safety and effectiveness of CD7 CAR-T cell therapy.ResultsAmong the 13 studies included in this study, a total of 200 patients received CD7 CAR-T cell therapy, including 88 patients who received autologous CAR-T cells, 112 patients who received donor derived CAR-T cells. 87% (80% -94%, I2=29.65%) of patients achieved complete remission. The incidence of cytokine release syndrome (CRS) was 94% (88% -98%, I2 =32.71%, p=0.12), while the incidence of severe CRS (grade ≥ 3) was 12% (5% -20%, I2=41.04%, p=0.06). As for the incidence of immune effector cell-associated neurotoxicity syndrome (ICANS), it is 4% (1% -7%, I2=0, p=0.72). Through analysis of the key clinical issues, we found that consolidation allogeneic hematopoietic stem cell transplantation (allo-HSCT) after CAR-T cell therapy can significantly improve survival and avoid recurrence. Therefore, we believe that the consolidation allo-HSCT after CD7 CAR-T cell therapy should be advocated. And patients who received CD7 CAR-T cell therapy without gene editing had significantly longer overall survival than those who received CD7 CAR-T cell therapy with gene editing. This suggests that gene edited CD7 CAR-T cells may pose some potential risks that limit the long-term survival of patients.ConclusionOur study confirms the efficacy and safety of CD7 CAR-T cells and provides research directions for the subsequent treatment.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=502896, identifier CRD42024502896. |
| format | Article |
| id | doaj-art-3baaf32400c544d695776872c1edd83b |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-3baaf32400c544d695776872c1edd83b2025-01-07T06:40:23ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14788881478888The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysisJile Liu0Yuxin An1Rui Sun2Xiaomei Zhang3Shujing Guo4Xuejin Gao5Mingfeng Zhao6First Center Clinical College, Tianjin Medical University, Tianjin, ChinaFirst Center Clinical College, Tianjin Medical University, Tianjin, ChinaNankai University School of Medicine, Nankai University, Tianjin, ChinaNankai University School of Medicine, Nankai University, Tianjin, ChinaFirst Center Clinical College, Tianjin Medical University, Tianjin, ChinaDepartment of Emergency, Tianjin First Central Hospital, Tianjin, ChinaDepartment of Hematology, Tianjin First Central Hospital, Tianjin, ChinaIntroductionCD7 chimeric antigen receptor T-cell (CAR-T cell) therapy is an emerging method for treating hematological malignancies, and is another breakthrough in CAR-T cell therapy.MethodsThis study summarizes the currently published clinical research results on CD7 CAR-T cells and evaluates the safety and effectiveness of CD7 CAR-T cell therapy.ResultsAmong the 13 studies included in this study, a total of 200 patients received CD7 CAR-T cell therapy, including 88 patients who received autologous CAR-T cells, 112 patients who received donor derived CAR-T cells. 87% (80% -94%, I2=29.65%) of patients achieved complete remission. The incidence of cytokine release syndrome (CRS) was 94% (88% -98%, I2 =32.71%, p=0.12), while the incidence of severe CRS (grade ≥ 3) was 12% (5% -20%, I2=41.04%, p=0.06). As for the incidence of immune effector cell-associated neurotoxicity syndrome (ICANS), it is 4% (1% -7%, I2=0, p=0.72). Through analysis of the key clinical issues, we found that consolidation allogeneic hematopoietic stem cell transplantation (allo-HSCT) after CAR-T cell therapy can significantly improve survival and avoid recurrence. Therefore, we believe that the consolidation allo-HSCT after CD7 CAR-T cell therapy should be advocated. And patients who received CD7 CAR-T cell therapy without gene editing had significantly longer overall survival than those who received CD7 CAR-T cell therapy with gene editing. This suggests that gene edited CD7 CAR-T cells may pose some potential risks that limit the long-term survival of patients.ConclusionOur study confirms the efficacy and safety of CD7 CAR-T cells and provides research directions for the subsequent treatment.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=502896, identifier CRD42024502896.https://www.frontiersin.org/articles/10.3389/fonc.2024.1478888/fullCD7 CAR-T cellchimeric antigen receptor T cellsT-lymphocyte hematologic malignanciesgene editingallogeneic stem cell transplantation |
| spellingShingle | Jile Liu Yuxin An Rui Sun Xiaomei Zhang Shujing Guo Xuejin Gao Mingfeng Zhao The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis Frontiers in Oncology CD7 CAR-T cell chimeric antigen receptor T cells T-lymphocyte hematologic malignancies gene editing allogeneic stem cell transplantation |
| title | The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis |
| title_full | The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis |
| title_fullStr | The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis |
| title_full_unstemmed | The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis |
| title_short | The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis |
| title_sort | efficacy and safety of cd7 chimeric antigen receptor t cell therapy for hematologic malignancies a systematic review and meta analysis |
| topic | CD7 CAR-T cell chimeric antigen receptor T cells T-lymphocyte hematologic malignancies gene editing allogeneic stem cell transplantation |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1478888/full |
| work_keys_str_mv | AT jileliu theefficacyandsafetyofcd7chimericantigenreceptortcelltherapyforhematologicmalignanciesasystematicreviewandmetaanalysis AT yuxinan theefficacyandsafetyofcd7chimericantigenreceptortcelltherapyforhematologicmalignanciesasystematicreviewandmetaanalysis AT ruisun theefficacyandsafetyofcd7chimericantigenreceptortcelltherapyforhematologicmalignanciesasystematicreviewandmetaanalysis AT xiaomeizhang theefficacyandsafetyofcd7chimericantigenreceptortcelltherapyforhematologicmalignanciesasystematicreviewandmetaanalysis AT shujingguo theefficacyandsafetyofcd7chimericantigenreceptortcelltherapyforhematologicmalignanciesasystematicreviewandmetaanalysis AT xuejingao theefficacyandsafetyofcd7chimericantigenreceptortcelltherapyforhematologicmalignanciesasystematicreviewandmetaanalysis AT mingfengzhao theefficacyandsafetyofcd7chimericantigenreceptortcelltherapyforhematologicmalignanciesasystematicreviewandmetaanalysis AT jileliu efficacyandsafetyofcd7chimericantigenreceptortcelltherapyforhematologicmalignanciesasystematicreviewandmetaanalysis AT yuxinan efficacyandsafetyofcd7chimericantigenreceptortcelltherapyforhematologicmalignanciesasystematicreviewandmetaanalysis AT ruisun efficacyandsafetyofcd7chimericantigenreceptortcelltherapyforhematologicmalignanciesasystematicreviewandmetaanalysis AT xiaomeizhang efficacyandsafetyofcd7chimericantigenreceptortcelltherapyforhematologicmalignanciesasystematicreviewandmetaanalysis AT shujingguo efficacyandsafetyofcd7chimericantigenreceptortcelltherapyforhematologicmalignanciesasystematicreviewandmetaanalysis AT xuejingao efficacyandsafetyofcd7chimericantigenreceptortcelltherapyforhematologicmalignanciesasystematicreviewandmetaanalysis AT mingfengzhao efficacyandsafetyofcd7chimericantigenreceptortcelltherapyforhematologicmalignanciesasystematicreviewandmetaanalysis |